TG Therapeutics, Inc., formerly Manhattan Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. As of September 13, 2012, the Company was developing two therapies targeting hematological malignancies. TGTX-1101 (ublituximab) is a third generation monoclonal antibody that targets a epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available phosphatidylinositol 3-kinases (PI3K) delta inhibitor. The Company�s product portfolio also includes AST-726. As of December 31, 2011, it owned 13% interest in the H Pharmaceuticals K/S (Hedrin JV).